Brought to you by 
Affibody, Swedish Orphan Biovitrum sign deal in the area of inflammation
16 Aug 2012
Executive Summary
Swedish Orphan Biovitrum AB (Sobi) and fellow Swedish biotech Affibody AB are allying over the next two years to discover and develop new inflammatory diseases therapies targeting interleukin-1 (IL-1).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Affibody, Swedish Orphan Biovitrum sign deal in the area of inflammation
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice